Actively Recruiting
Evaluating Tumor-Informed ctDNA to Detect Residual or Recurrent Disease in Muscle-Invasive Bladder Cancer The TiMBER Observational Study
Led by OHSU Knight Cancer Institute · Updated on 2026-08-14
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the Labcorp Plasma Detect assay to detect circulating tumor DNA ctDNA in patients with muscle-invasive urothelial carcinoma, a form of bladder cancer. This observational study aims to understand how ctDNA levels relate to cancer recurrence and treatment response by analyzing tissue, blood, and urine samples. The research team will also review medical records to better understand this cancer type and patient outcomes. Participants will provide blood, tissue, and urine samples for testing during the study. These samples will be used for whole genome sequencing of their cancer to assess tumor DNA levels. The study does not involve any treatment interventions but focuses on observation and sample analysis to evaluate ctDNA presence and its correlation with disease status. Throughout the study, participants will have their medical records reviewed and samples collected prospectively. Researchers will measure the concordance between ctDNA status and cancer recurrence over the study period, which may continue up to five years depending on interim results. This long-term monitoring helps assess disease status and treatment response without requiring additional treatments as part of the study.
CONDITIONS
Brief Title
Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here